Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/Tacrolimus
| Autor: | O. Richter, K. Kohlhaw, J. Hauss, M Wenzke, T. Lohmann, J. Seissler, P. Lamesch, C. Schwarz, C. List |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Autoimmunity Liver transplantation Tacrolimus Islets of Langerhans Endocrinology Insulin resistance Internal medicine Diabetes mellitus Diabetes Mellitus polycyclic compounds Internal Medicine medicine Humans geography geography.geographical_feature_category C-Peptide business.industry Insulin General Medicine Glucose Tolerance Test Middle Aged medicine.disease Islet Lipids Liver Transplantation Transplantation Cyclosporine Prednisolone Female business Immunosuppressive Agents medicine.drug |
| Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 108:347-352 |
| ISSN: | 1439-3646 0947-7349 |
| DOI: | 10.1055/s-2000-8127 |
| Popis: | The induction of diabetes has been recognised as adverse effect of the immunsuppressive drug FK506/Tacrolimus. The aim of this study was to clarify whether insulinopenia or insulin resistance dominates and whether islet cell autoantibodies are present in patients treated by FK506. We investigated 58 patients 1-3 years after liver transplantation while under therapy with FK506 or CsA and prednisolone (0-7.5 mg) for basal blood glucose levels and islet-cell specific autoantibodies. A subgroup of 20 patients on FK506, 10 patients on cyclosporin and 15 healthy volunteers were metabolically tested by oGTT. Five patients had diabetes pre-transplantation. After transplantation, 9/28 FK506-treated patients developed newly diagnosed diabetes compared to 0/25 cyclosporin-treated patients (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|